Hospitals File Emergency Court Order to Block 340B Rebate Pilot — Third Litigation Front Opens

Hospital plaintiffs filed an emergency motion in late April / early May 2026 seeking an injunction against HRSA's 340B Rebate Model Pilot Program, alleging irreparable harm. This is the third litigation front against the rebate model: (1) the AHA/MHA Maine District Court case that already vacated the original rebate notice in February 2026, (2) the AHA en banc petition in the 4th Circuit on the WV contract pharmacy law, and now (3) this emergency injunction filing. The HRSA RFI (April 20) and ICR (April 27) comment periods both closed with industry-unified opposition (AHA, NACHC, ASHP, WHA all filed). HHS is now in review phase before any pilot relaunch. If the emergency motion succeeds, the rebate pilot is frozen nationally — direct cash-flow protection for FQHC pharmacy economics. If it fails, FQHCs face the prospect of paying full price upfront with 30-90 day rebate lag. CA FQHCs heavily 340B-dependent (AltaMed, FHCSD, San Ysidro, Vista Community Clinic, Asian Health Services, La Clinica de la Raza) should be running both scenarios in their FY26-27 cash flow projections. Pairs with the AbbVie 340B patient-definition lawsuit (April 8) and the Lilly/Novo claims-data mandate already active.